Brihad Abhyankar
Chief Tech/Sci/R&D Officer bei MORPHIC HOLDING, INC.
Ursprung des Netzwerks ersten Grades von Brihad Abhyankar
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA.
17
| Subsidiary | Biotechnology | 17 |
| Public Company | Pharmaceuticals: Major | 16 | |
| Public Company | Biotechnology | 4 | |
Theravance Biopharma US, Inc.
 Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA.
2
| Subsidiary | Miscellaneous Commercial Services | 2 |
Takeda Pharmaceuticals Europe Ltd.
 Takeda Pharmaceuticals Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Pharmaceuticals Europe Ltd. provides management services. The private company is based in Westminster, UK. The CEO of the British company is Trevor Smith.
2
| Extinct | Miscellaneous Commercial Services | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Brihad Abhyankar
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA. | Miscellaneous Commercial Services | Comptroller/Controller/Auditor | |
| GILEAD SCIENCES, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| CUBIST PHARMACEUTICALS INC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| ATYR PHARMA, INC. | Pharmaceuticals: Major | Chief Executive Officer Private Equity Analyst | |
| GENOCEA BIOSCIENCES, INC. | Biotechnology | Chief Administrative Officer | |
Nimbus Therapeutics LLC
 Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
| TRANSLATE BIO, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| SQZ BIOTECHNOLOGIES COMPANY | Biotechnology | Director/Board Member Director/Board Member | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree Undergraduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Chief Executive Officer | |
| MITHRA PHARMACEUTICALS S.A. | Pharmaceuticals: Major | Chief Executive Officer | |
| INFINITY PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree | |
| Bentley University | College/University | Undergraduate Degree Undergraduate Degree | |
| Yale University | College/University | Doctorate Degree Doctorate Degree | |
| Tufts University | College/University | Undergraduate Degree Undergraduate Degree | |
| University of California, Berkeley | College/University | Undergraduate Degree Graduate Degree | |
| University of California, Irvine | College/University | Doctorate Degree Doctorate Degree | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Director/Board Member | |
| TXCELL | Miscellaneous Commercial Services | Director/Board Member | |
| PHARNEXT SCA | Biotechnology | Chief Executive Officer | |
| Tuck School of Business at Dartmouth | College/University | Masters Business Admin Masters Business Admin | |
| ADVICENNE | Pharmaceuticals: Generic | Chairman | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| Columbia University College of Physicians & Surgeons | College/University | Corporate Officer/Principal | |
Biosplice Therapeutics, Inc.
 Biosplice Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Biosplice Therapeutics, Inc. provides medical research and development for tissue-level regeneration. It develops therapeutics to address a range of degenerative diseases, regenerative medicine and oncology. The company was founded by Osman Kibar and John Hood in 2008 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Biotechnology | Founder Director/Board Member | |
| REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| OMEGA ALPHA SPAC | Financial Conglomerates | Director/Board Member Chief Executive Officer | |
Dewpoint Therapeutics, Inc.
 Dewpoint Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Dewpoint Therapeutics, Inc. develops drugs. The company is headquartered in Boston, MA. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| SCHOLAR ROCK HOLDING CORPORATION | Biotechnology | Founder Director/Board Member | |
Tectonic Therapeutic, Inc.
 Tectonic Therapeutic, Inc. Miscellaneous Commercial ServicesCommercial Services Tectonic Therapeutic, Inc. is a biotech company based in Watertown, MA. Tectonic is focused on transforming the discovery of antibodies and other biologic drugs targeting G-protein coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company's proprietary Geode platform aims to unlock the therapeutic utility of the most difficult receptors in the class, which have been considered undruggable with small molecules. The company was founded by Timothy A. Springer and Andrew Kruse of Harvard Medical School. Alise S. Reicin has been the CEO of the company since 2020. | Miscellaneous Commercial Services | Founder Director/Board Member | |
Institute For Protein Innovation, Inc.
 Institute For Protein Innovation, Inc. Miscellaneous Commercial ServicesCommercial Services Institute For Protein Innovation, Inc. is a non-profit company that focuses on enhancing the potential of recombinant antibodies. The company is based in Boston, MA. The company uses sophisticated yeast display technology to generate synthetic, recombinant antibodies. The company was founded by Andrew Kruse, Timothy A. Springer. Kenneth Fasman has been the CEO of the company since 2022. | Miscellaneous Commercial Services | Founder Director/Board Member | |
| KRONOS BIO, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Ixaka Ltd.
 Ixaka Ltd. BiotechnologyHealth Technology Ixaka Ltd. engages in the development of advanced cell-based therapeutics for the treatment of critical limb ischemia. The company was founded by Gaby Salem and Vicente Saez Gonzalez in 2015 and is headquartered in London, the United Kingdom. | Biotechnology | Chairman | |
Rectify Pharmaceuticals LLC
 Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Miscellaneous Commercial Services | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 38 |
| Vereinigtes Königreich | 4 |
| Frankreich | 4 |
| Belgien | 2 |
| Norwegen | 2 |
Sektoral
| Health Technology | 26 |
| Consumer Services | 12 |
| Commercial Services | 9 |
| Finance | 3 |
Operativ
| Director/Board Member | 204 |
| Corporate Officer/Principal | 69 |
| Independent Dir/Board Member | 49 |
| Chief Executive Officer | 32 |
| Undergraduate Degree | 23 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Amir Nashat | 49 |
| Martin Edwards | 38 |
| Otello Stampacchia | 37 |
| Nilesh Kumar | 26 |
| David Solomon | 22 |
| Susannah Gray | 20 |
| Joseph Slattery | 18 |
| Timothy Springer | 17 |
| Gur Roshwalb | 17 |
| Vikas Goyal | 16 |
| Mark Murcko | 14 |
| Gustav Christensen | 14 |
| Praveen Tipirneni | 11 |
| Norbert W. Bischofberger | 11 |
| Marc Schegerin | 11 |
- Börse
- Insiders
- Brihad Abhyankar
- Unternehmensverbindungen
